Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Chemotherapy in Advanced Ovarian Cancer
NCT03410784Phase 2Unknown
- Sponsor
- National Cancer Institute
- Start
- Apr 2018
- Primary completion
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by National Cancer Institute. Status: unknown.
02
Drugs
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT03410784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03410784.